BNGO · Bionano Genomics, Inc.

Bionano Genomics delivered Q1 2026 results showing modest top-line growth with total revenue reaching $6.7 million, a 4% increase from $6.5 million in the prior year quarter, primarily fueled by strong consumables performance up 20% to $3.9 million and a 17% rise in flow cell sales to 8,178 units. This reflects sustained engagement from the installed base and positive utilization trends in optical genome mapping (OGM) and VIA software, as highlighted by interim CEO Al Luderer. Gross margins expanded to 49% from 46%, matching adjusted margins, signaling improved cost efficiencies amid product mix shifts. Operating expenses saw a 2% GAAP reduction to $11.1 million, though adjusted expenses rose 7% to $9.1 million, indicating disciplined cost management. Key business catalysts include the January 1, 2026, activation of Category I CPT code 81354 for OGM in constitutional genetic disorders, priced above microarray peers, and a 47% payment hike for hematologic malignancy code 81195 to $1,853.22. Scientific momentum continues with new publications validating OGM's superiority in multiple myeloma, gene editing, and rare diseases, plus robust adoption evidenced at the Bionano Symposium 2026 with over 1,250 attendees. Management's outlook projects Q2 revenue of $7.5-7.8 million and full-year $30-33 million, underpinned by expanding evidence and global adoption. A pivotal balance sheet event looms with the anticipated retirement of secured convertible debt, freeing capital for growth initiatives and bolstering financial flexibility.